Foghorn Therapeutics
Jenny Klinger, CPA, currently serves as the VP of Financial Planning and Analysis at Foghorn Therapeutics Inc. since October 2024. Prior to this role, Jenny held the position of Head of Financial Planning and Analysis at Disc Medicine from November 2021 to October 2024 and progressed through various leadership positions at Seres Therapeutics, including Senior Director and Director of Financial Planning and Analysis. Additional experience includes serving as Associate Director of US and Global Forecasting at Sanofi Genzyme, Senior Finance Manager roles at Epizyme and FORUM Pharmaceuticals, and Senior Financial Analyst at Biogen. Jenny began their career at Partners HealthCare and Goldman Sachs, with foundational experience as an Associate at KPMG US. Educational qualifications include an MBA from Northwestern University - Kellogg School of Management and an MS in Accountancy from the University of Illinois Urbana-Champaign, complemented by a BA in Economics and Finance from Providence College.
This person is not in any teams
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.